Form 4: Pfizer SVP & Controller Receives Equity Grants

Pfizer's SVP & Controller, Jennifer B. Damico, reported significant equity grants and a tax-related share disposition.

Summary

• Jennifer B. Damico, SVP & Controller of Pfizer Inc., reported transactions involving the company's common stock and stock appreciation rights.
• On March 3, 2026, Damico was granted 16,311 shares of common stock and an additional 5,408 shares of common stock, both as restricted stock units subject to vesting, with an acquisition price of $0.00 per share.
• Following these grants, her direct beneficial ownership of common stock increased to 33,760 shares.
• Also on March 3, 2026, Damico was granted 22,638 Stock Appreciation Rights (SARs) with an exercise price of $26.58 and an acquisition price of $0.00. These SARs are subject to vesting and will be settled in Pfizer common stock on March 3, 2031.
• On March 4, 2026, 826 shares of common stock were disposed of at a price of $26.62 per share to satisfy tax obligations upon the vesting of restricted stock units.
• After all reported transactions, Damico beneficially owns 32,934 shares of common stock and 22,638 Stock Appreciation Rights.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting ongoing executive compensation and alignment of interests, with no unexpected negative implications. The grants indicate continued commitment to the executive.

Positives

• Grant of 16,311 shares of common stock as restricted stock units on March 3, 2026.
• Grant of 5,408 shares of common stock as restricted stock units on March 3, 2026.
• Grant of 22,638 Stock Appreciation Rights (SARs) on March 3, 2026, aligning management incentives with shareholder value.
• Transactions were executed under a Rule 10b5-1(c) plan, indicating pre-planned equity management.

Negatives

• Disposition of 826 shares of common stock at $26.62 on March 4, 2026, to cover tax obligations, which reduces direct beneficial ownership.

Industry Context

StockSavvy.ai notes that equity grants, including restricted stock units and stock appreciation rights, are standard components of executive compensation packages in the pharmaceutical industry, designed to align executive interests with long-term shareholder value. The use of a 10b5-1 plan is also a common practice for insiders to manage their equity holdings in a compliant manner.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and SARs, is consistent with practices observed at major pharmaceutical companies such as Johnson & Johnson (JNJ), Merck & Co. (MRK), and Bristol-Myers Squibb (BMY), where similar long-term incentive vehicles are used to retain talent and incentivize performance.
• The disposition of shares for tax withholding upon vesting is a routine and expected event for equity compensation across all industries, not unique to pharmaceuticals.

Related Party Transactions

• The grants of restricted stock units and Stock Appreciation Rights to Jennifer B. Damico, an SVP & Controller, constitute related party transactions as they are part of her compensation from Pfizer Inc.

Stakeholder Impact

• Shareholders: The grants align executive incentives with shareholder value, potentially encouraging long-term performance. The disposition for taxes is a minor, routine event.
• Employees: Reflects standard executive compensation practices within the company.
• Management: Jennifer B. Damico's equity stake increases, strengthening her financial interest in the company's success.

Next Steps

• Vesting of restricted stock units according to their specific schedules.
• Settlement of Stock Appreciation Rights in Pfizer common stock on March 3, 2031, subject to vesting requirements.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation grants and a tax-related share disposition, which are standard events for publicly traded companies. It does not provide new material information that would significantly alter the investment thesis for Pfizer Inc. The transactions are pre-planned under a 10b5-1 plan, indicating no discretionary trading based on new insider information. Therefore, a "hold" recommendation is appropriate as this filing alone does not warrant a change in investment strategy.

Keywords

Pfizer, PFE, Jennifer B. Damico, SVP & Controller, SEC Form 4, insider trading, equity grant, restricted stock units, RSU, stock appreciation rights, SARs, executive compensation, 10b5-1 plan